This episode delves into a real-world case study of a Phase 1 clinical trial, focusing on the challenges and key takeaways from the experience. We follow the journey of a new drug designed to treat a neurological condition, highlighting the complexities of oral drug delivery and the unexpected safety signals encountered during the trial, such as gastrointestinal problems and elevated liver enzymes. The discussion emphasizes the importance of adaptive trial protocols, which allow researchers to make adjustments based on emerging data, and the crucial role of FDA and ICH guidelines in guiding these decisions. The episode showcases how researchers balance the need to learn as much as possible about the drug with the paramount importance of patient safety.

Beyond the specific case study, the episode explores broader lessons learned about how Ph ...